KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.80

Temazepam or Melatonin Versus Placebo for the Treatment of Insomnia in Advanced Cancer: A Three-Arm, Double-Blind, Phase III, Multicenter, Randomized Clinical Trial.

Ruwani Mendis, Aaron Wong, Simon Frenkel, Anne Marie Southcott, Chris J Selman, Jennifer Martin, Anneke Grobler, David Currow, Meera Agar, Brian Le, Jennifer Philip

J Palliat Med 27(10) 1368-1373

PMID39304187
PMCID-
DOI10.1089/jpm.2024.0151
发表日期2024-09-20
入排依据:The study meets criteria for oncology, human, randomized, Phase III, drug intervention, and original results, but the primary endpoint is a patient-reported symptom score (ISI), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
摘要

摘要

Background: Sleep disturbance has a prevalence of 30-78% in patients with advanced cancer. While pharmacotherapy is common, randomized controlled studies (RCTs) investigating available agents are limited. This study examines the efficacy and safety of temazepam or melatonin versus placebo for sleep in advanced cancer. Methods: This is a multicenter, randomized, double-blind, placebo-controlled study of temazepam, melatonin prolonged release (PR) or placebo for insomnia in patients with advanced cancer, and an insomnia severity index (ISI) score of >11. Results: Twenty-one participants were randomized: nine to temazepam, eight to melatonin, and four to placebo. Baseline characteristics between groups were similar. The adjusted mean difference in day 8 ISI score versus placebo was -9.1 (95% confidence interval [CI] -17.5, 0.7, p = 0.04) for temazepam and -9.6 (95% CI -18,-1.2, p = 0.03) for melatonin PR. There was no improvement in global quality of life. Both agents were well tolerated. Conclusion: Temazepam and melatonin PR were associated with a clinically significant improvement in patient-reported insomnia severity compared with placebo. Findings need confirmation with larger patient numbers.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。